AXL and sarcoma: Consistently, here we demonstrated that pAXL×CD3ε indeed redirects T cells toward AXL-expressing sarcoma cells, leading to a dose-dependent T-cell activation, with a consequent release of inflammatory cytokines and cytolytic molecules.